Venus Remedies novel research product ‘Vancoplus’ receives US patent

03 Aug 2011 Evaluate

Venus Remedies has received its first patent from US PTO for its novel research product, Vancoplus. With this patent grant, which is valid up to December 2027, the company is set to tap the US market by launching the product.

Vancoplus has already been granted the patents from countries like South Africa, New Zleand and Ukraine. Vancoplus, a brand  of Ceftriaxone  and  Vancomycin along with the  chemical  vector, used in  CVMC technology, is the only  remedy  after vaccination  to treat MRSA  and multi  drug resistant  microbes  which causes  Meningities, Pneumonia, Typhoid, Septicemia, Urinary  Treat infection, skin and  skin infections  and staphylococcal  Endocarditis, The drug restricts  the production  of toxin  by MRSA pathogens and also  reduces the treatment  time, cost and  adverse affects.

Vancoplus which took more than  seven years  after its development  to receive the US  patent  is intended  to be launched  in early 2014 through 505(b)(2) route.

Venus Remedies Share Price

755.25 14.50 (1.96%)
31-Dec-2025 14:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.00
Dr. Reddys Lab 1270.00
Cipla 1506.65
Zydus Lifesciences 913.10
Lupin 2110.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×